Program
nesuparib
Its studies are mostly in Stomach Neoplasms · Ovarian Neoplasms, led by Jeil Pharmaceutical.
Furthest: phase 2, since Jul 13, 20224 company-led studies, 3 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jeil Pharmaceutical | 43 open or running | phase 2since Jul 13, 2022 | Jan 31, 2018 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 31, 2018First study: phase 1 study in Advanced Solid TumorsFirst studyNCT04335604 · 62 enrolled · Korea, Republic of
- Jul 13, 2022Phase 2 study in Ovarian NeoplasmsNCT05475184 · 58 enrolled · Korea, Republic of
- Jan 11, 2026Phase 2 study in Stomach NeoplasmsNCT07364422 · 49 planned · South Korea
- Apr 15, 2026Phase 1 study in Healthy VolunteersNCT07570186 · 36 planned · South Korea
TargetBeta
“An orally bioavailable second-generation inhibitor of the nuclear enzymes poly(ADP-ribose) polymerase (PARP) type 1 (PARP1) and 2 (PARP2) and tankyrase (TNK; TNKS; TANK) 1 and 2, ”NCIt, by rule
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07570186Healthy Volunteers · South Korea | 1 | Not yet recruiting | Jul 2026 | 36 |
| NCT07364422Stomach Neoplasms · South Korea | 2 | Not yet recruiting | Feb 28, 2026 | 49 |
| NCT05475184Ovarian Neoplasms · Korea, Republic of | 2 | Active, not recruiting | Nov 2024 | 58 |
| NCT04335604Advanced Solid Tumors · Korea, Republic of | 1 | Completed | Dec 14, 2021 | 62 |
How it is read
Names in the registry
- “JPI-547”, 4 entries
Conditions, from the studies’ own filings
- Stomach Neoplasms, 1 study
- Ovarian Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.